Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer.
about
Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired ResistancePredictive Factors for Switched EGFR-TKI Retreatment in Patients with EGFR-Mutant Non-Small Cell Lung Cancer.Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancerNear Total Regression of Diffuse Brain Metastases in Adenocarcinoma of the Lung with an EGFR Exon 19 Mutation: A Case Report and Review of the LiteratureErlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancerClinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis.Clinical significance of gefitinib antitumor activity in patients with lung adenocarcinoma.Total en bloc thoracic and lumbar spondylectomy for non-small cell lung cancer with favorable prognostic indicators: is it merely indicated for solitary spinal metastasis?Drug rechallenge and treatment beyond progression--implications for drug resistance.Second Complete Remission of Relapsed Stage IV Non-Small Cell Lung Cancer Following Retreatment.Poorer prognosis in Taiwanese female ever smokers with stage IV lung adenocarcinoma who were readministered a tyrosine kinase inhibitor.Repeated favorable responses to epidermal growth factor receptor-tyrosine kinase inhibitors in a case of advanced lung adenocarcinoma.Predictors of survival in patients with bone metastasis of lung cancerPooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancersEffects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.Treatment of Non-small Cell Lung Carcinoma after Failure of Epidermal Growth Factor Receptor Tyrosine Kinase InhibitorEffect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice.Re-administration after the failure of gefitinib or erlotinib in patients with advanced non-small cell lung cancer.Phase II study of erlotinib as a salvage treatment for non-small-cell lung cancer patients after failure of gefitinib treatment.Post-progression survival in patients with non-small cell lung cancer with clinically acquired resistance to gefitinib.Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.Long Term Therapeutic Plan for Patients with Non-Small Cell Lung Cancer Harboring EGFR Mutation.Plasma T790M and HGF as potential predictive markers for EGFR-TKI re-challenge.Remarkable Effect of Gefitinib Retreatment in a Lung Cancer Patient With Lepidic Predominat Adenocarcinoma who had Experienced Favorable Results From Initial Treatment With Gefitinib: A Case Report.Surgical treatment of a patient with lung cancer metastasized to the spine with EGFR mutation: A case report.Long-term survival of a patient with lung cancer metastasis to the spine following surgical treatment combined with radiation and epithelial growth factor receptor inhibitor therapy: A case report.[Clinical response to gefitinib retreatment of lung adenocarcinoma patients who benefited from an initial gefitinib therapy: a retrospective analysis].
P2860
Q28083239-51739157-313B-4A63-84C5-CE7E01032B33Q33567383-DC014B16-5FE3-4A00-853E-A7446A979600Q33834851-58CEF8D5-6357-4B19-B664-D563BC0CA9A9Q34075381-6299545B-774F-4126-AF25-6C6424EB7CBEQ34159240-C02E7BFE-DF4B-45AD-A2CD-F149B6B16EADQ34500155-4EDE9F3F-0D28-4801-AE59-C93A5D96E45EQ34582813-79A38F89-28EA-4480-8521-B70FA87114AEQ34749897-68B9C7CF-B447-4608-96CE-3B8E64A63146Q35967416-0F61D3AF-DFB6-40E3-B48C-9498893D1F85Q36434328-4E1B6683-9A18-41EE-8D79-37C751C18103Q36710172-6A791C14-7430-426E-AF21-4E416893B37BQ36741917-8C020526-BAD5-401D-8734-263432A1E48EQ36826129-A2E77012-328B-48B2-BAB3-7B9CA5F08B13Q36905639-3804B707-6B3E-4D21-9519-73CB8EEB77BBQ37000538-927E6090-AE89-46DC-B4F3-DFD94B3FB12EQ37011144-7B2726AB-8DBF-46E6-909B-31E2C5FBD772Q37090804-2EA0120F-71F5-432D-98CA-0C49168F4572Q37128041-0EC28854-1B08-4B9C-B904-216507AA73F9Q37321925-F47EF41A-D577-4F2C-8406-BD405D5443DEQ37329579-A0EDC8F9-E442-40F5-9C22-325BD99770DEQ37379113-8584DC48-4F29-40AD-845C-29438CBD4C24Q37575209-010DE94E-75E5-4E2B-BBB4-1736AD44A146Q38673986-07D73E6A-E7FB-403D-A525-7942E0F54796Q41767944-3EF7934B-75B1-433C-B826-9523298C1868Q41940272-EDFB2DD5-4307-4CF7-AA76-56BAD8833A96Q42118804-C8338A5C-F03A-41F4-80E9-D8AD7046B477Q54536910-552A9F3A-EFCD-451C-8ABA-68525B6708A7
P2860
Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer.
description
2007 nî lūn-bûn
@nan
2007 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մարտին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Clinical benefit of readminist ...... th non-small cell lung cancer.
@ast
Clinical benefit of readminist ...... th non-small cell lung cancer.
@en
type
label
Clinical benefit of readminist ...... th non-small cell lung cancer.
@ast
Clinical benefit of readminist ...... th non-small cell lung cancer.
@en
prefLabel
Clinical benefit of readminist ...... th non-small cell lung cancer.
@ast
Clinical benefit of readminist ...... th non-small cell lung cancer.
@en
P2093
P2860
P1433
P1476
Clinical benefit of readminist ...... ith non-small cell lung cancer
@en
P2093
Hiroshi Isobe
Hiroshi Yokouchi
Hirotoshi Dosaka-Akita
Ichiro Kinoshita
Jun Konishi
Kenji Akie
Koichi Yamazaki
Masao Harada
Mitsuru Munakata
Noriaki Sukoh
P2860
P2888
P356
10.1186/1471-2407-7-51
10.1186/1471-2407-7-S1-A51
P407
P577
2007-03-20T00:00:00Z
P6179
1028158164